A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s disease associated with Mycobacterium avium subspecies paratuberculosis

Table 1 MIC of the proprietary RHB-104 capsule formulation and RHB-104 analog

Microorganism	Minimum inhibitory concentration (μg/mL)
Microorganism	CLA-CLO-RIF (RHB-104 analog)^a	Proprietary RHB-104 capsule formulation^b
MAP MS 137	4.0	2.0
M. avium—JF7	4.0	2.0
M. fortuitum ss fortuitum	15	10
M. tuberculosis HR237	10	5.0
M. smegmatis ATCC 27199	6.0	0.125
S. aureus ATCC 25923	0.25	0.125
L. monocytogenes ATCC 19112	0.5	0.25
K. pneumonia ATCC 13883	>40	>40
Recombinant E. coli	>40	>40

All cultures were performed in duplicates and have been repeated three times
^aRHB-104 analog where the 3 drugs dissolved individually were combined in one solution at their proprietary RHB-104 capsule formulation composition percentage
^bProprietary RHB-104 capsule formulation was dissolved in one compatible solvent

ISSN: 1757-4749